<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959957</url>
  </required_header>
  <id_info>
    <org_study_id>FoHM/UVI 2015</org_study_id>
    <secondary_id>2015-003898-15</secondary_id>
    <nct_id>NCT02959957</nct_id>
  </id_info>
  <brief_title>Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections</brief_title>
  <official_title>A Randomized, Controlled, Multicentre Trial of Collateral Damage on the Intestinal Microbiota Inferred by Temocillin Versus Cefotaxime in Patients Receiving Empirical Treatment for Febrile Urinary Tract Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Håkan Hanberger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Public Health Agency of Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the ecological impact on the intestinal microbiota and compare the
      safety and efficacy of temocillin compared to cefotaxime, in empiric treatment of febrile
      UTI. Half of participants will receive temocillin and the other half will receive cefotaxime.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Temocillin is a narrow spectrum antibiotic with activity against gram negative bacteria
      inclusive many ESBL producing bacteria. Temocillin is approved and marketed in a few European
      countries since the 1980´s but not in Sweden.

      The aim of the study is to find an ecological favorable alternative to cephalosporins in the
      treatment of this common indication.

      The hypothesis is that treatment with temocillin causes less disturbances on the intestinal
      microbiota while at least comparable efficacy.

      The study will be performed as an open prospective multicentre study with two parallel groups
      comparing 2 g temocillin three times daily with 1-2 g cefotaxim three times daily for 7-10
      days in male and female adult patients with febrile urinary tract infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with emergence of any of the two following events: Colonisation or infection with C. difficile and/or with Enterobacteriaceae resistant to 3rd generation cephalosporins. Measured in cultures from faecal samples.</measure>
    <time_frame>Within 12 hours after the last dose of study drug.</time_frame>
    <description>Superiority analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinical cure in each treatment group.</measure>
    <time_frame>7-10 days after discontinuation of antibiotic treatment (parenteral and oral).</time_frame>
    <description>Clinical cure defined as patient totally recovered with no remaining symptoms of UTI or no recurrence with symptoms or no need of further treatment against the current infection. Non-inferiority analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with early clinical response.</measure>
    <time_frame>Within 12 hours after the 9th dose of study drug.</time_frame>
    <description>Non-inferiority analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological cure per patient and per pathogen measured as negative urine Culture &lt;1000 CFU/ml.</measure>
    <time_frame>7-10 days after discontinuation of antibiotic treatment (parenteral and oral).</time_frame>
    <description>Non-inferiority analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early bacteriological response measured as negative urine Culture &lt;1000 CFU/ml.</measure>
    <time_frame>Within 12 hours after the 9th dose of study drug.</time_frame>
    <description>Non-inferiority analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with diarrhea (≥ 3 loose stools per day)</measure>
    <time_frame>From the first dose of study drug until 7-10 days after discontinuation of antibiotic treatment (parenteral and oral).</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>From the first dose of study drug until 4-6 weeks after discontinuation of antibiotic treatment (parenteral and per oral).</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Temocillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefotaxime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temocillin</intervention_name>
    <description>Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.</description>
    <arm_group_label>Temocillin</arm_group_label>
    <other_name>Negaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefotaxime</intervention_name>
    <description>Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.</description>
    <arm_group_label>Cefotaxime</arm_group_label>
    <other_name>Claforan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females ≥ 18 years of age with suspected or confirmed febrile UTI,
             fulfilling at least one of the following signs and symptoms:

               -  Flank pain or suprapubic pain, Tenderness over the kidney on physical
                  examination, Urinary symptoms such as dysuria, urinary frequency or urinary
                  urgency

          -  Fever ≥ 38.0°C (highest temperature recorded at home or at the hospital)

          -  Positive urinalysis tests (U-Nitrit and/or U-LPK)

          -  Have a pre-treatment baseline urinary culture obtained

          -  Require iv antibacterial treatment of the presumed infection

          -  Fertile women: Agree to practice highly effective anti-contraceptive methods from
             study-start to TOC

          -  Signed informed consent

        Exclusion Criteria:

          -  Have a documented history of hypersensitivity or allergic reaction to any beta-lactam

          -  Pregnant or nursing women

          -  Receipt of any prior potentially therapeutic antibacterial agent within 1 month before
             randomisation and sampling for urine and faecal cultures. Exceptions will prior
             treatment with pivmecillinam or nitrofurantoin.

          -  Known chronic renal insufficiency (creatinine clearance &lt; 10 mL/min at screening as
             estimated by Cockcroft-Gault), or receiving intermittent haemodialysis or peritoneal
             dialysis

          -  Known colonization with ESBL

          -  Any condition or circumstance that, in the opinion of the investigator, would
             compromise the safety of the subject or the quality of study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Håkan Hanberger, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Linkoeping</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotta Edlund, Professor</last_name>
    <phone>+46102052011</phone>
    <email>charlotta.edlund@folkhalsomyndigheten.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gunilla Skoog, M. Sci. Ph.</last_name>
    <phone>+46102052406</phone>
    <email>gunilla.skoog@folkhalsomyndigheten.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danderyd University Hospital</name>
      <address>
        <city>Danderyd</city>
        <state>Stockholm</state>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper Ericsson</last_name>
      <email>jesper.ericsson@ds.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <state>Stockholm</state>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Ternhag</last_name>
      <email>anders.ternhag@karolinska.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>416 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Bremell</last_name>
      <email>daniel.bremell@infect.gu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <zip>251 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Karin Lindgren</last_name>
      <email>Anna-Karin.A.Lindgren@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Åse Östholm Balkhed</last_name>
      <email>ase.ostholm.balkhed@lio.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisela Otto</last_name>
      <email>gisela.otto@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capio S:t Görans hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Holmström</last_name>
      <email>daniel.holmstrom@capiostgoran.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sundsvall Hospital</name>
      <address>
        <city>Sundsvall</city>
        <zip>856 43</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Tempé</last_name>
      <email>maria.tempe@lvn.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Furberg</last_name>
      <email>maria.furberg@umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Athlin</last_name>
      <email>simon.athlin@regionorebrolan.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Östersund Hospital</name>
      <address>
        <city>Östersund</city>
        <zip>83131</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elin Hedman</last_name>
      <email>elin.hedman@regionjh.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Public Health Agency of Sweden</investigator_affiliation>
    <investigator_full_name>Håkan Hanberger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
    <mesh_term>Temocillin</mesh_term>
    <mesh_term>Penicillins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

